logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Hauptversammlung
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Mechanism of Action

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection


by Sovereign

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect


by Sovereign

Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway


by Sovereign

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity


by Sovereign

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent


by Sovereign

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA


by Sovereign

Characterization of the ribonuclease activity on the skin surface


by Sovereign

Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro


by Sovereign

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas


by Sovereign

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA


by Sovereign

  • 1
  • 2
  • 3